Antioxidant properties of bilirubin have been reported in many studies. We hypothesized that bilirubin might be involved in neuroprotection mechanisms against oxidative stress in infants with hypoxic-ischemic encephalopathy (HIE) and that total serum bilirubin (TSB) might increase in these patients. We retrospectively studied infants with gestational age ≥ 35 weeks and birth weight ≥ 1800 g who were admitted to the neonatal intensive care unit (NICU) with a diagnosis of moderate-to-severe HIE and received or did not receive therapeutic hypothermia. We evaluated peak TSB and changes of mean TSB in these patients in comparison with a control group of infants admitted to the NICU with diagnoses other than HIE. Peak and mean TSB values were lower in the no hypothermia and hypothermia groups in comparison with the control group, while differences were not noted between infants who received hypothermia or did not. Regression analysis showed that HIE and hypothermia significantly reduced the risk of developing TSB values higher than median value (> 8.4 mg/dL) in our population.
Introduction
Hypoxic-ischemic encephalopathy (HIE) is a clinical syndrome in late preterm and term infants that results from a severe or prolonged cerebral hypoxic-ischemic episode before or during birth. Its incidence ranges from one to eight per 1000 live births in developed countries and is as high as 26 per 1000 live births in underdeveloped countries [21] .
Infants who have suffered HIE have an increased risk of death and lifelong disability, such as cerebral palsy, cognitive impairment, developmental delay, visual and learning impairment, and epilepsy [3, 7] . Nowadays, therapeutic hypothermia has been established as a standard of care for infants diagnosed with moderate-to-severe HIE. In fact, there is evidence that cooling, when initiated within 6 h from birth, reduces mortality without increasing major disability in survivors in late preterm and term infants [16] . Nevertheless, therapeutic hypothermia is only partially effective, with almost 50% of treated infants having adverse outcomes [11] .
The pathophysiology of HIE is complex and includes acute effects of cell energy failure, due to hypoxia and low intake of glucose, and extracellular accumulation of excitatory amino acids that lead to cell death via necrosis and apoptotic cascades [10, 32, 33] . This primary phase is followed, from 1 to 6 h after the acute injury, by excitotoxicity phenomena, deterioration of mitochondrial function, inflammation, increased reactive oxygen species (ROS) and nitric oxide production, and accumulation of intracellular Ca 2+ that continues the activation of apoptotic cascades (latent phase) [10, 33] . Then, from 6 to 15 h after the initial insult, cytotoxic edema, excitotoxicity, and secondary energy failure with nearly complete failure of mitochondrial activity occur during the secondary phase and cause further cell death [10, 33] . Finally, a tertiary phase is characterized by late cell death, astrogliosis, and remodeling of the injured brain [10, 33] .
The role of oxidative stress in the pathophysiology of HIE has been elucidated in many studies [10, 26, 33] . ROS have important functions in cell signaling and physiological regulations, but under pathological circumstances such as hypoxia-ischemia or reperfusion-reoxygenation, they are believed to participate in tissue degenerative processes leading to the acute and chronic brain injury [9] . Acute injuries are represented by alterations to structural components of cells like receptors, transporters, and respiratory complexes, while chronic injuries consist in defective genetic information from oxidative alterations to nucleic acids resulting in defective proteins [26] .
On the other hand, it has been suggested that bilirubin is involved in the balance of newborns' antioxidant and prooxidant agents, which is particularly challenged in the transitional post-natal period. Many studies have demonstrated the antioxidant properties of bilirubin whose reactions involve free radicals or toxic products of oxygen reduction [22] . In particular, unconjugated bilirubin can scavenge singlet oxygen with high efficiency, react with superoxide anions and peroxyl radicals, and serve as a reducing substrate for peroxidases in the presence of hydrogen peroxide or organic hydroperoxides [29, 30] . Moreover, when bound to serum albumin, bilirubin can protect linoleic acid from peroxyl radicalinduced oxidation [30] . However, although the antioxidant effect of bilirubin as a scavenger of ROS is well documented in in vitro [23, 29, 31, 34] and animal studies [8] , its role in vivo in term infants with or without jaundice [4, 5, 8, 13, 20, 36] is still debated. Similarly, changes of total serum bilirubin (TSB) in infants with HIE have been poorly studied [6, 19, 24, 37] , and the potential neuroprotective role of bilirubin as antioxidant agent has not been evaluated.
Thus, we hypothesized that brain neuroprotection mechanisms against oxidative stress might include bilirubin synthesis and that bilirubin might be involved in neuroprotection mechanisms against oxidative stress in infants with hypoxic-ischemic encephalopathy (HIE). Therefore, the aim of this study was to assess changes of TSB in a cohort of late preterm and term infants with HIE who were treated or not with therapeutic hypothermia in comparison to a cohort of infants without HIE.
Materials and methods
This retrospective study was carried out at the neonatal intensive care unit (NICU) of the Careggi University Hospital of Florence following approval by the Tuscan pediatric ethics committee. Inborn infants with gestational age ≥ 35 weeks and birth weight ≥ 1800 g who were admitted to the NICU with the diagnosis of moderate-to severe HIE from January 2002 to December 2018 were included in the study. We introduced therapeutic hypothermia starting in January 2010, and therefore, this treatment was carried out in infants born after this date. Exclusion criteria were major congenital malformation and inherited metabolic disorders. The diagnosis of HIE was based on a low Apgar score (≤ 5 at 10 min of life), metabolic acidosis (pH ≤ 7.00 or BE > 12-16 mmol/L in arterial cord oxygen or newborn blood oxygen levels within 60 min of life), and clinical signs of encephalopathy (depression of the level of consciousness, respiratory depression, abnormality of muscle tone and power, disturbances of cranial nerve function, seizures) [2] . Clinical severity of HIE was evaluated according to Sarnat grading system which identifies it into three categories: mild (stage I), moderate (stage II), and severe (stage III) forms [28] . For this study, only infants with moderate-to severe HIE were evaluated and could receive therapeutic hypothermia. The control group included inborn infants with gestational age ≥ 35 weeks and birth weight ≥ 1800 g without hepatic diseases admitted to the NICU with diagnoses other than HIE (i.e., transient, tachypnea of the newborn, mild transient hypoglycemia, unexpected episodes of cyanosis) immediately before or after the admission of an infant with HIE included in the study.
We performed systemic hypothermia maintaining central body temperature in the range of 33.0 to 34.0°C for 72 h starting within the first 6 h of life and following the guidelines of the Italian Society of Neonatology [2] . TSB was measured in whole blood from a heel prick sample in a blood gas analyzer with a spectrophotometer module in infants who presented with visible jaundice. Hematocrit was measured simultaneously. Entry criteria to phototherapy followed the American Academy of Pediatrics recommendations [1] until 2014 when the Italian Society of Neonatology recommendations were introduced in our center [27] .
Infants' records were examined and the following data were recorded for each patient: gestational age, birth weight, gender, type of delivery, Apgar score at 1 and 5 min, main maternal diseases, such as premature rupture of membrane (PROM), chorioamionitis, and placental abruption, ABO incompatibility, positive Coombs test, cord blood pH, BE, and lactate, hematocrit at 1 and 5 days of life, Sarnat stage [28] , seizures, treatment with phenobarbital, RMN brain injuries, need for phototherapy, and duration of hospital stay.
Moreover, we evaluated peak values of TSB and changes of mean TSB values that occurred in the first 5 days of life in the study groups.
Statistical analysis
Data are reported as mean values and standard deviations, median values and ranges, or rates and percentages. We analyzed continuous variables using Student's t test and categorical variables with χ 2 test. Moreover, repeated measures ANOVA test was used for analyzing intra-group changes of TSB. A p < 0.05 was considered statistically significant.
We then included the variables most probably related to TSB levels in the multiple linear regression analysis to assess their possible independent effects in our population. Effect estimates are expressed as relative risk (RR) with profile likelihood-based 95% confidence limits. The reported RRs represent the effect of gestational age ≤ or > 39 weeks, birth weight ≤ or > 3250 g, hematocrit ≤ or > 54.0 or 49.0% at 1 and 5 days of life, respectively, treatment with phenobarbital, HIE, and therapeutic hypothermia on the risk of developing TSB values higher than the median peak value measured in our population (8.4 mg/dL). These values of gestational age, birth weight, and hematocrit were decided upon because they represent the median values in our population.
A post hoc analysis, using the study's sample size and observed differences of peak TSB value between infants with HIE and controls (7.5 ± 3.9 vs. 10.1 ± 3.8 mg/dL), demonstrated that the statistical power of our study was 85.5%, at an alpha of 0.05 and a beta of 0.8.
Results
We studied 40 infants with HIE and 40 controls. Twenty infants with HIE were treated with hypothermia and 20 were not. Infants' clinical characteristics are detailed in Table 1 . Infants in the hypothermia group had more frequent seizures, phenobarbital treatment, RMN cerebral injuries, and longer hospital stays than in infants in the no hypothermia group (Table 1) .
None of the infants in the hypothermia group needed phototherapy compared to four (20%) infants in the no hypothermia group and eight (20%) infants in the control group; however, differences were not statistically significant (Table 1) .
Peak TSB values were lower in the no hypothermia and hypothermia groups in comparison to the control group. Mean TSB values were lower in the no hypothermia and hypothermia groups in comparison to the control group, and differences became significant in the second day of life in the hypothermia group and in the third day of life in the no hypothermia group. We did not find any differences in TSB values between infants in the hypothermia and no hypothermia group ( Table 2 , Fig. 1) .
The median TSB value in our population was 8. 
Discussion
In this study, we assessed changes of TSB in a cohort of late preterm and term infants with moderate-to-severe HIE, who received or did not receive therapeutic hypothermia, in comparison to a cohort of infants admitted to the NICU with diagnoses other than HIE. We found that infants with HIE either treated or untreated with hypothermia have lower peak TSB and lower mean TSB values than controls. Moreover, we found that HIE and hypothermia independently decrease the risk of developing TSB values > 8.4 mg/dL.
Yu et al. [37] studied 15 term infants with HIE and found that TSB measured within the first 24 h of life was similar to that of healthy controls. Karlsson et al. [19] compared TSB values in 26 infants with mild-to-severe HIE to those of healthy full-term infants during the first days of life and they found that TSB was similar in infants with HIE and controls during the first 3 days of life, but was lower between the sixth and twelfth days of life. It is worth noting that in this latter study, 14 (25%) infants with clinical jaundice were excluded from the analysis of mean TSB in the control group; this choice did not allow an actual comparison of infants with HIE, since it excluded those who probably had highest TSB values [19] . Choudhary et al. [25] studied 70 term infants with mild-to-severe HIE and found that TSB measured within the first day of life was lower than in healthy controls. However, they did not find any differences when TSB was measured on the third and tenth day of life [6] . Thus, our findings agree with Yu [37] and Karlsson [19] , since we confirmed that TSB is similar in infants with and without HIE in the first day of life, yet disagree with Karlsson [19] and Choudhary [6] , since we found that TSB is lower in infants with HIE than in controls from the third to the fifth day of life. On the other hand, our population was different from previous studies [6, 19, 24] because our patients had more severe HIE and received therapeutic hypothermia in half of cases. Moreover, previous investigations [6, 19, 24] did not report on phototherapy in studied infants, and it is impossible to evaluate its possible confounding effect on data analysis and results.
Our results exclude the possibility that an increase of TSB can act as neuroprotective antioxidant agent in infants with HIE. On the contrary, the observed lower TSB values might represent a neuroprotective mechanism. In fact, in vitro studies in immature rat neurons demonstrate that bilirubin can enhance hypoxia injuring effects reducing cell viability by facilitating glutamate-mediated apoptosis [14, 15] . Moreover, it has been demonstrated that preconditioning cultured rat astrocytes with hypoxia or combined oxygen-glucose deprivation increases their vulnerability to bilirubin damage by enhancing cell death by both apoptosis and necrosis [12] . Thus, our findings may be clinically relevant because they suggest the possible existence of mechanisms preventing infants who suffered brain hypoxicischemic injuries during the perinatal period from later developing of a neonatal hyperbilirubinemia that might increase risks for cerebral damages and encephalopathy. In fact, other in vitro studies demonstrate that hypoxia represses HO expression: Nakayama et al. [25] found that expression of HO-1 mRNA is repressed by hypoxia in primary cultures of human umbilical vein endothelial cells; Kitamuro et al. [18] confirmed that hypoxia represses HO-1 expression with the induction of Bach1, a heme-regulated transcriptional repressor, in human cells, and Zhang et al. [38] demonstrated that hypoxia represses HO-2 First, the repression of HO-1 expression can reduce high energy expenditure consumed for heme catabolism catalyzed by HO-1 in conditions of energy failure, such as cerebral hypoxia-ischemia [18, 25] . Second, it prevents the local accumulation of carbon monoxide, iron, and bilirubin in the HO-1-expressing cells, thereby preventing the tissue damage induced by these molecules [18, 25] . And third, it might represent a mechanism by which the intra-cellular heme level is maintained at a stable range contributing to regulate HO expression [18, 25] . Therefore, it has been suggested that the hypoxic repression of HO-1 expression represents a hitherto unrecognized defense strategy under hypoxia in certain cell types [25] , such as neurons and astrocytes in infants with HIE, and our findings seem to indirectly confirm this speculation.
Our multiple linear regression analysis supports the independent contribution of hypothermia in limiting bilirubin synthesis in infants with HIE possibly by decreasing HO expression and/ or activity. The only previous clinical study on this matter was by Muniraman et al. [24] who studied 361 infants with gestational age ≥ 36 weeks with mild-to-moderate HIE. They found a similar median peak TSB [6.0 (0.8-21.8) vs. 7.1 (1.0-14.6) mg/dL) with respect to ours which occurred in the third day of life as in our population [24] . Some of their patients (38%) were treated with hypothermia, and, in agreement with our results, peak TSB values of these infants were higher than those of infants who did not receive hypothermia, although the difference was not statistically significant [24] . However, in disagreement with our findings, the multivariate regression analysis showed no effect of hypothermia on peak TSB level [24] . On the other hand, the effect of hypothermia on HO expression is still debated [17, 35] give conflicting results. Thus, additional studies are needed to evaluate the effect of therapeutic hypothermia on TSB level in infants with HIE. The limitation of our study includes its retrospective design which did not allow measurement of oxidative stress in our patients and its correlation with TSB level; the lack of a healthy control group; and the size of our population which did not allow result stratification by HIE severity (moderate or severe).
In conclusion, we found that peak TSB and mean TSB values were lower in late preterm and term infants with moderate-to-severe HIE treated or untreated with hypothermia than in control infants. HIE and hypothermia were found to be independent risk factors for developing TSB higher than the median value in our population. These results exclude that an increase of TSB may act as neuroprotective antioxidant agent in infants with HIE. On the contrary, we speculated that hypoxic repression of HO expression might represent a defensive strategy for limiting brain injuries in infants who suffer HIE.
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